{"id":"active-comparator-erlotinib","safety":{"commonSideEffects":[{"rate":"75","effect":"Rash"},{"rate":"54","effect":"Diarrhea"},{"rate":"33","effect":"Nausea"},{"rate":"23","effect":"Vomiting"},{"rate":"52","effect":"Fatigue"},{"rate":"52","effect":"Anorexia"},{"rate":"26","effect":"Dyspnea"},{"rate":"1","effect":"Interstitial lung disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Erlotinib selectively inhibits the intracellular tyrosine kinase domain of EGFR, preventing autophosphorylation and downstream signaling through the MAPK and PI3K/AKT pathways. This leads to cell cycle arrest and apoptosis in EGFR-dependent tumors. It is particularly effective in non-small cell lung cancers harboring activating EGFR mutations.","oneSentence":"Erlotinib is a tyrosine kinase inhibitor that blocks epidermal growth factor receptor (EGFR) signaling to inhibit cancer cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:09.658Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer with EGFR mutations"},{"name":"Locally advanced or metastatic pancreatic cancer (in combination with gemcitabine)"}]},"trialDetails":[{"nctId":"NCT02193282","phase":"PHASE3","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-02-11","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":390},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT02759614","phase":"PHASE3","title":"Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations","status":"COMPLETED","sponsor":"Guangdong Association of Clinical Trials","startDate":"2016-04-01","conditions":"NSCLC","enrollment":311},{"nctId":"NCT01013649","phase":"PHASE3","title":"Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04-05","conditions":"Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm","enrollment":546},{"nctId":"NCT02152631","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-10-03","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT01897480","phase":"PHASE2","title":"A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-08-28","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":168},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT03137771","phase":"PHASE2","title":"Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2017-04-07","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer","enrollment":218},{"nctId":"NCT01771458","phase":"PHASE2","title":"A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2012-10","conditions":"Reccurent/Metastatic Solid Tumor Disease","enrollment":742},{"nctId":"NCT03498521","phase":"PHASE2","title":"A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-10","conditions":"Cancer of Unknown Primary Site","enrollment":529},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT05442060","phase":"PHASE2","title":"To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"OBI Pharma, Inc","startDate":"2022-07-27","conditions":"Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT06483555","phase":"PHASE1, PHASE2","title":"Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2025-02-06","conditions":"Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm","enrollment":104},{"nctId":"NCT00446225","phase":"PHASE3","title":"Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2007-02-15","conditions":"Non-Small Cell Lung Cancer","enrollment":174},{"nctId":"NCT01032070","phase":"PHASE2","title":"Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma","status":"TERMINATED","sponsor":"OSI Pharmaceuticals","startDate":"2010-09-27","conditions":"Recurrent or Refractory Pediatric Ependymoma","enrollment":25},{"nctId":"NCT02588261","phase":"PHASE3","title":"A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-02-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":530},{"nctId":"NCT01306045","phase":"PHASE2","title":"Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic","enrollment":647},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT01064479","phase":"PHASE2","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-02-05","conditions":"Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx, Metastatic Squamous Cell Carcinoma of the Oral Cavity","enrollment":123},{"nctId":"NCT04401059","phase":"PHASE4","title":"Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study","status":"RECRUITING","sponsor":"Tian Xie","startDate":"2020-11-09","conditions":"Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma","enrollment":744},{"nctId":"NCT05081674","phase":"PHASE2","title":"Brazilian Lung Immunotherapy Study","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2020-01-01","conditions":"Lung Neoplasm","enrollment":154},{"nctId":"NCT04591431","phase":"PHASE2","title":"The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy","status":"UNKNOWN","sponsor":"Fondazione per la Medicina Personalizzata","startDate":"2020-10-07","conditions":"Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer","enrollment":400},{"nctId":"NCT01068587","phase":"PHASE1, PHASE2","title":"MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2010-01-21","conditions":"Lung Cancer","enrollment":31},{"nctId":"NCT01104155","phase":"PHASE2","title":"Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-02-22","conditions":"Non-small Cell Lung Cancer","enrollment":123},{"nctId":"NCT02045446","phase":"PHASE2","title":"Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-02","conditions":"Stage IV Non-Small Cell Lung Cancer","enrollment":29},{"nctId":"NCT02633189","phase":"PHASE3","title":"Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2016-04","conditions":"Non-squamous Non-small Cell Lung Cancer","enrollment":200},{"nctId":"NCT01487174","phase":"PHASE3","title":"KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy","status":"TERMINATED","sponsor":"Kadmon Corporation, LLC","startDate":"2011-12-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":8},{"nctId":"NCT03126799","phase":"PHASE2","title":"A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2016-11-01","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":128},{"nctId":"NCT00617708","phase":"PHASE1, PHASE2","title":"S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-03","conditions":"Stage IV Pancreatic Cancer","enrollment":134},{"nctId":"NCT04165031","phase":"PHASE1, PHASE2","title":"A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2019-11-28","conditions":"Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Cancer","enrollment":5},{"nctId":"NCT04874844","phase":"PHASE2, PHASE3","title":"JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety","status":"UNKNOWN","sponsor":"Beijing Dongfang Biotech Co., Ltd.","startDate":"2021-07-30","conditions":"NSCLC","enrollment":420},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT03595644","phase":"PHASE2","title":"Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2017-02-12","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":74},{"nctId":"NCT01244191","phase":"PHASE3","title":"Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer","status":"TERMINATED","sponsor":"Daiichi Sankyo","startDate":"2011-01-11","conditions":"Non Squamous, Non-small-cell Lung Cancer","enrollment":1048},{"nctId":"NCT00570258","phase":"PHASE2","title":"Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2006-09","conditions":"Metastatic Breast Cancer","enrollment":27},{"nctId":"NCT02714530","phase":"PHASE2","title":"Thoracal Radiotherapy and Tarceva","status":"TERMINATED","sponsor":"Oslo University Hospital","startDate":"2014-04-01","conditions":"Cancer","enrollment":118},{"nctId":"NCT00606502","phase":"PHASE2","title":"Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2008-01","conditions":"Non-small Cell Lung Cancer","enrollment":201},{"nctId":"NCT02893332","phase":"PHASE3","title":"Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)","status":"TERMINATED","sponsor":"Sichuan Provincial People's Hospital","startDate":"2016-01-15","conditions":"Stage IV EGFR Mutated Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT01556191","phase":"PHASE2","title":"Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2012-05-15","conditions":"Stage IV Lung Cancer","enrollment":379},{"nctId":"NCT00456833","phase":"PHASE1","title":"Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-06","conditions":"Non Small Cell Lung Cancer","enrollment":248},{"nctId":"NCT02318368","phase":"PHASE2","title":"A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label","status":"TERMINATED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2014-11","conditions":"Non-small Cell Lung Cancer","enrollment":10},{"nctId":"NCT01532089","phase":"PHASE2","title":"Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2012-03-16","conditions":"EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":88},{"nctId":"NCT00835471","phase":"PHASE2","title":"2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Dutch Society of Physicians for Pulmonology and Tuberculosis","startDate":"2009-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":195},{"nctId":"NCT00950365","phase":"PHASE2","title":"Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2006-04","conditions":"Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma","enrollment":79},{"nctId":"NCT04455594","phase":"PHASE2","title":"Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2020-10","conditions":"Non-Small Cell Lung Cancer Stage IIIA","enrollment":168},{"nctId":"NCT01101334","phase":"PHASE2","title":"Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2010-03","conditions":"Advanced Non-small Cell Lung Cancer (NSCLC)","enrollment":90},{"nctId":"NCT00026338","phase":"PHASE3","title":"Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2001-10-29","conditions":"Pancreatic Cancer","enrollment":569},{"nctId":"NCT02926638","phase":"PHASE2, PHASE3","title":"Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches","status":"TERMINATED","sponsor":"SWOG Cancer Research Network","startDate":"2014-06-16","conditions":"MET Positive, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7","enrollment":9},{"nctId":"NCT03119519","phase":"PHASE2","title":"Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.","status":"UNKNOWN","sponsor":"Southern Medical University, China","startDate":"2017-12-11","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":148},{"nctId":"NCT00661193","phase":"PHASE2","title":"S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2008-12","conditions":"Lung Cancer","enrollment":59},{"nctId":"NCT02117024","phase":"PHASE2","title":"A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2014-07","conditions":"Non Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT03529084","phase":"PHASE3","title":"Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-24","conditions":"Carcinoma, Non-small Cell Lung","enrollment":""},{"nctId":"NCT04145570","phase":"PHASE4","title":"A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions","status":"COMPLETED","sponsor":"Quadras Scientific Solutions","startDate":"2008-10-23","conditions":"Lung Cancer","enrollment":24},{"nctId":"NCT01822496","phase":"PHASE2","title":"Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-11-04","conditions":"Stage III Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7","enrollment":59},{"nctId":"NCT00901901","phase":"PHASE3","title":"Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05-21","conditions":"Carcinoma, Hepatocellular","enrollment":732},{"nctId":"NCT00300586","phase":"PHASE3","title":"IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2006-06","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":842},{"nctId":"NCT01116219","phase":"PHASE2","title":"Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-06","conditions":"Lung Cancer","enrollment":149},{"nctId":"NCT02186301","phase":"PHASE2, PHASE3","title":"TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy","status":"TERMINATED","sponsor":"Clovis Oncology, Inc.","startDate":"2014-11","conditions":"Non-Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT02775006","phase":"PHASE3","title":"Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"The Netherlands Cancer Institute","startDate":"2016-10-14","conditions":"Carcinoma, Non-small Cell Lung","enrollment":45},{"nctId":"NCT02556593","phase":"PHASE2","title":"IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2015-09","conditions":"Non-Small Cell Lung Carcinoma","enrollment":12},{"nctId":"NCT01518621","phase":"PHASE2","title":"Whole Brain Radiation With or Without Erlotinib for Brain Metastases From Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Oslo University Hospital","startDate":"2012-05","conditions":"Cancer","enrollment":25},{"nctId":"NCT02355431","phase":"PHASE2","title":"Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations","status":"WITHDRAWN","sponsor":"Incyte Corporation","startDate":"2014-12","conditions":"Solid Tumors and Hematologic Malignancy, NSCLC (Non-small Cell Lung Carcinoma)","enrollment":""},{"nctId":"NCT00100854","phase":"PHASE2","title":"Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Translational Oncology Research International","startDate":"2004-10-28","conditions":"Lung Cancer","enrollment":108},{"nctId":"NCT01523587","phase":"PHASE3","title":"LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-03-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":795},{"nctId":"NCT01407822","phase":"PHASE2, PHASE3","title":"Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Guangdong Association of Clinical Trials","startDate":"2011-12-05","conditions":"Non-small Cell Lung Cancer","enrollment":72},{"nctId":"NCT00654420","phase":"PHASE2","title":"A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03-19","conditions":"Carcinoma, Non-small-cell Lung","enrollment":95},{"nctId":"NCT02655536","phase":"PHASE2","title":"Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-08-01","conditions":"Carcinoma, Non-Small-Cell Lung, Brain Neoplasms","enrollment":109},{"nctId":"NCT02004262","phase":"PHASE2","title":"Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting","status":"COMPLETED","sponsor":"Aduro Biotech, Inc.","startDate":"2014-02-05","conditions":"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer","enrollment":303},{"nctId":"NCT01395758","phase":"PHASE2","title":"Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","startDate":"2011-07","conditions":"Metastatic Non-Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT03461185","phase":"PHASE2","title":"Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2018-05-01","conditions":"Non Small Cell Lung Cancer","enrollment":100},{"nctId":"NCT00096265","phase":"PHASE3","title":"Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-06","conditions":"Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7","enrollment":126},{"nctId":"NCT00462995","phase":"PHASE2","title":"Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2006-05","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT00364351","phase":"PHASE3","title":"Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-08","conditions":"Non Small Cell Lung Cancer","enrollment":1574},{"nctId":"NCT03389256","phase":"PHASE2","title":"Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC","status":"UNKNOWN","sponsor":"Sichuan Cancer Hospital and Research Institute","startDate":"2018-12-30","conditions":"Lung Diseases, Neoplasms, Respiratory Tract Diseases","enrollment":144},{"nctId":"NCT00230126","phase":"PHASE2","title":"OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2005-10","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":57},{"nctId":"NCT00428194","phase":"PHASE1","title":"Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-01","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT02714010","phase":"PHASE3","title":"EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-Small Cell Lung Cancer","enrollment":601},{"nctId":"NCT01351415","phase":"PHASE3","title":"A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-06-25","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":485},{"nctId":"NCT00881751","phase":"PHASE2","title":"Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2009-03","conditions":"Liver Cancer","enrollment":95},{"nctId":"NCT01303029","phase":"PHASE2","title":"Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2011-02","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT01729481","phase":"PHASE2","title":"Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2012-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":150},{"nctId":"NCT02178397","phase":"PHASE3","title":"A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR","status":"TERMINATED","sponsor":"Centre Francois Baclesse","startDate":"2014-06","conditions":"NSCLC Patients With EGFR Activating Mutation","enrollment":6},{"nctId":"NCT02064491","phase":"PHASE2","title":"Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC","status":"COMPLETED","sponsor":"Finnish Lung Cancer Group","startDate":"2014-02","conditions":"Non-small Cell Lung Cancer","enrollment":18},{"nctId":"NCT01360554","phase":"PHASE3","title":"ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06-16","conditions":"Non-Small Cell Lung Cancer","enrollment":878},{"nctId":"NCT01229150","phase":"PHASE2","title":"Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-26","conditions":"Non Small Cell Lung Carcinoma","enrollment":89},{"nctId":"NCT01256437","phase":"PHASE2","title":"Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash","status":"COMPLETED","sponsor":"Rabin Medical Center","startDate":"2011-01","conditions":"Acneiform Rash","enrollment":90},{"nctId":"NCT00283244","phase":"PHASE2","title":"Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2006-03","conditions":"Lung Cancer","enrollment":147},{"nctId":"NCT03123484","phase":"PHASE2","title":"β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2017-04","conditions":"Non Small Cell Lung Cancer","enrollment":80},{"nctId":"NCT00392665","phase":"PHASE2","title":"Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2006-10","conditions":"Squamous Cell Carcinoma of the Head and Neck (SCCHN)","enrollment":36},{"nctId":"NCT00550836","phase":"PHASE2","title":"Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2009-03","conditions":"Pancreatic Cancer","enrollment":104},{"nctId":"NCT01085136","phase":"PHASE3","title":"LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":1154},{"nctId":"NCT00499655","phase":"PHASE2","title":"Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-11","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":107},{"nctId":"NCT03071705","phase":"NA","title":"Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2016-03","conditions":"Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation","enrollment":120},{"nctId":"NCT00775385","phase":"PHASE2, PHASE3","title":"TAilored Post-Surgical Therapy in Early Stage NSCLC","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2009-04","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":152},{"nctId":"NCT01024413","phase":"PHASE3","title":"Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations","status":"COMPLETED","sponsor":"Chinese Society of Lung Cancer","startDate":"2009-07","conditions":"Thoracic Neoplasms","enrollment":256},{"nctId":"NCT01714908","phase":"PHASE2","title":"Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21","status":"UNKNOWN","sponsor":"Jinming Yu","startDate":"2012-12-14","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT01383148","phase":"PHASE2, PHASE3","title":"Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Transgene","startDate":"2012-04","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":222},{"nctId":"NCT02795884","phase":"PHASE3","title":"Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation","status":"WITHDRAWN","sponsor":"Yonsei University","startDate":"2016-06","conditions":"NSCLC","enrollment":""},{"nctId":"NCT01887886","phase":"PHASE3","title":"A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-12","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":10},{"nctId":"NCT01683175","phase":"PHASE2","title":"Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2012-08","conditions":"Non-small Cell Lung Cancer Stage III","enrollment":94}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1016,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Active Comparator (erlotinib)","genericName":"Active Comparator (erlotinib)","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erlotinib is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) used to treat EGFR-positive non-small cell lung cancer. It is classified as an INHIBITOR and works by inhibiting the EGFR erbB1.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}